Department of the Army January 13, 2014 – Federal Register Recent Federal Regulation Documents
Results 1 - 5 of 5
Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Anti-Filovirus Therapeutics
Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/761,942, entitled ``Anti-Filovirus Therapeutics,'' filed on February 7, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.
Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Low Fat, High Protein, High Carbohydrate Complete Enteral Nutritional Compositions for Treatment of Burn Patients
Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/733,938, entitled ``Low Fat, High Protein, High Carbohydrate Complete Enteral Nutritional Compositions for Treatment of Burn Patients,'' filed on December 6, 2012. The United States Government, as represented by the Secretary of the Army, has rights to this invention.
Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Imidazenil, or a Combination of Imidazenil and [+]-Huperzine A and/or [-]-Huperzine A for Protection Against and/or Treatment of Seizure/Status Epilepticus and Neuropathology Following Nerve Agent or Organophosphate Exposure, Compositions and Kits
Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/726,753, entitled ``Imidazenil, or a Combination of Imidazenil and [+]-Huperzine A and/or [-]-Huperzine A for Protection Against and/or Treatment of Seizure/Status Epilepticus and Neuropathology Following Nerve Agent or Organophosphate Exposure, Compositions and Kits,'' filed on November 15, 2012. The United States Government, as represented by the Secretary of the Army, has rights to this invention.
Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Contact Pathway and Tissue Kallikrein Inhibitors Can Prevent/Reduce Leakage Caused by Hantavirus
Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/851,573, entitled ``Contact Pathway and Tissue Kallikrein Inhibitors can Prevent/Reduce Leakage Caused by Hantavirus,'' filed on March 15, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.
Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Measurements of the Inhibition of Synaptic Activity (MISA) To Detect, Study and Evaluate All Active Botulinum Neurotoxin Serotypes
Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/851,599, entitled ``Measurements of the Inhibition of Synaptic Activity (MISA) to Detect, Study and Evaluate All Active Botulinum Neurotoxin Serotypes,'' filed on March 8, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
